Roche Harmony NIPT 22q11.2 Deletion

Roche has added 22q11.2 deletion testing to the Harmony Prenatal Test menu, allowing laboratories and physicians using the test to screen for 22q11.2 deletion syndrome, which is associated with heart defects, poor immune system function, cleft palate, and delayed development. The 22q11.2 deletion is estimated to occur in one out of every 2,000 to 4,000 live births.


DNANexus Mosaic Microbiome Research Platform

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.